- First presentation of topline clinical data from Phase 1 SAD/MAD trial of VG-3927 for the potential treatment of Alzheimer’s disease (AD) - “We are thrilled to showcase our preclinical and Phase 1 ...
PIMCO Dynamic Income Strategy Fund (PDX) trades at a steep 10.4% discount to NAV, driven by Venture Global (VG) underperformance and arbitration risks. PDX's discount is now almost equal to the value ...
Venture Global, Inc. (NYSE:VG) is included among the 12 Best LNG Stocks to Buy According to Hedge Funds. Merely a startup a few years ago, Venture Global, Inc. (NYSE:VG) has grown to become the second ...
Vigil Neuroscience reported positive Phase 1 trial results for VG-3927 and plans a Phase 2 trial in Q3 2025. Vigil Neuroscience, Inc. announced promising outcomes from a Phase 1 clinical trial of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results